Andreassen et al. evaluated remimazolam, a novel ultra-short-acting benzodiazepine, for procedural sedation in the emergency department (ED). This prospective single-center study (Aalborg University Hospital, May-August 2024) assessed effectiveness and patient satisfaction. The study enrolled 103 patients: 53 treated by emergency medicine physicians (group 1) and 50 by nurse anesthetists (group 2). Endpoints included procedural success, patient-reported outcomes, sedation onset and recovery times, and adverse events. Respiratory effects were mild or absent in 97% of patients in group 1 and in all patients in group 2. Procedural amnesia was present in 93% of patients in group 1 and 90% in group 2, and pain relief was reported by the majority of patients across both groups. Patients were said to be left unsupervised a median of 15 minutes after sedation in both groups, and procedural success was achieved in 92% of group 1 versus 100% of patients in group 2. Sedation quality was consistently high and the adverse effects were infrequent and manageable across both groups.